[Personalized treatment in non-small cell lung cancer]

MeSH terms

• Adenocarcinoma / drug therapy*
• Adenocarcinoma / enzymology
• Adenocarcinoma / genetics
• Adenocarcinoma / secondary
• Algorithms
• Antineoplastic Agents / therapeutic use
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Bone Neoplasms / drug therapy
• Bone Neoplasms / enzymology
• Bone Neoplasms / secondary
• Carcinoma, Non-Small-Cell Lung / drug therapy*
• Carcinoma, Non-Small-Cell Lung / enzymology
• Carcinoma, Non-Small-Cell Lung / genetics
• Clinical Trials, Phase II as Topic / statistics & numerical data
• Crizotinib
• ErbB Receptors / antagonists & inhibitors*
• ErbB Receptors / genetics
• Erlotinib Hydrochloride
• Female
• Genes, ras
• Humans
• Leiomyoma / surgery
• Lung Neoplasms / drug therapy*
• Lung Neoplasms / enzymology
• Lung Neoplasms / genetics
• Middle Aged
• Molecular Targeted Therapy*
• Neoplasm Proteins / antagonists & inhibitors*
• Neoplasm Proteins / genetics
• Neoplasms, Second Primary / drug therapy
• Neoplasms, Second Primary / enzymology
• Neoplasms, Second Primary / genetics
• Oncogene Proteins, Fusion / antagonists & inhibitors*
• Oncogene Proteins, Fusion / genetics
• Precision Medicine*
• Protein Kinase Inhibitors / therapeutic use*
• Pyrazoles / therapeutic use*
• Pyridines / therapeutic use*
• Quinazolines / therapeutic use*
• Randomized Controlled Trials as Topic / statistics & numerical data
• Uterine Neoplasms / surgery